Moderna shares plunge over 25% on apparent cancer vaccine data leak
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Moderna shares plunged more than 25% on Thursday, while Merck fell over 3%, after what appeared to be an early release of closely watched clinical trial results for the companies' experimental cancer vaccine. Still guessing which stocks will beat the market? Our…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bearishAn apparent early release of cancer vaccine trial data can strongly move shares of Moderna and Merck.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna shares fell more than 25% on Thursday.
- 02Merck fell over 3% in the same session.
- 03The results were briefly published on Oncology Central before being taken down.
- 04The combined vaccine with Keytruda reportedly cut the risk of melanoma recurrence or death by 42%.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Moderna, Inc.187.47 USD+1.17%today -23.73%Negative Merck & Co., Inc.148.72 USD+0.65%today -0.77%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets